Contrea

Founded in 2020 and located in Tokyo, Japan, Contrea, Inc. , d. b. a Contrea engages in the development and management of MediOS, a platform designed to link doctors and patients.

This platform employs video technology to assist doctors in their routine explanations and offers patients visual medical information. Additionally, it alleviates the workload of medical professionals by automating pre-operative interviews and managing viewing logs. The company is led by CEO Kawabata Kazuhiro, who has a history of entrepreneurship. In January 2026, Contrea, Inc.

raised an undisclosed amount  in series A funding led by ITOCHU Technology Ventures, with participation from SBI Shinsei Corporate Investment, Global Brain, Globe Advisors Ventures, DBJ Capital, Nippon Venture Capital, Hakuhodo DY Ventures, Mizuho Capital, Mitsui Sumitomo Insurance Venture Capital, MINNANO MARKET K. K. , Aflac Ventures Japan and Mizuho Bank. The round was part of a larger JPY 950 million series A and debt funding.

Contrea, Inc. primarily offers a healthcare communication platform known as MediOS. This innovative system bridges the gap between healthcare providers, such as doctors, nurses, and clerks, and patients, enhancing collaboration and improving overall care experiences. MediOS is designed to streamline workflows by allowing medical professionals to focus on their core responsibilities while facilitating effective communication with patients.

Released as part of the company's strategic initiative to transform the healthcare landscape through informed consent processes, MediOS serves a diverse client base that includes hospitals and clinics across various regions. The company's products are primarily marketed within Japan, although they have aspirations to expand into other geographic markets. The revenue structure of Contrea, Inc. revolves around B2B transactions, with healthcare institutions subscribing to the MediOS platform for enhanced patient-provider communication.

Clients engage with Contrea through subscription agreements, where they pay for access to the platform based on the level of service and the number of users within their institution. This transactional model allows healthcare providers to integrate MediOS into their daily operations effectively. While specific pricing plans for MediOS are not disclosed, the company's flagship product's value proposition lies in its ability to optimize healthcare delivery processes, which can lead to significant cost savings and improved patient outcomes for subscribing healthcare organizations. In November 2021, Contrea, Inc.

raised JPY 142 million in pre-Series A funding. The company plans to utilize these funds to expand video content, develop a system for smoother user experience, and strengthen its sales and marketing strategy to reform doctors' working styles by 2024. Contrea is also looking to expand its market reach beyond Japan, although specific targeted regions have not been defined. The company plans to use the January 2026 funding to enhance both the product and organizational framework, in addition to establishing new business ventures.